OTEZLA OFFERS EFFICACY IN DMARD-NAÏVE PATIENTS1
OTEZLA monotherapy reduces tender and swollen joint count in DMARD-naïve patients1,a
aPALACE 4 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Randomized patients who received ≥1 dose of study medication: OTEZLA 30 mg BID, n = 176; placebo, n = 176. The n at each time point represents the number of patients with available data at the time point.
OTEZLA EFFECTIVELY RELIEVES PREEXISTING DACTYLITIS AND ENTHESITIS IN DMARD-NAÏVE PATIENTS1*
- At 4 years, among patients receiving OTEZLA, 80.9% achieved resolution of dactylitis and 64% achieved resolution of enthesitis†
- During the placebo-controlled phase, at week 16, percent change in dactylitis count was -69.2% with OTEZLA 30 mg BID vs -50.0% for placebo (P = 0.1494); percent change in MASES (enthesitis) score was -50% vs 0%, respectively (P = 0.0006)
*Patients with enthesitis and dactylitis at baseline: OTEZLA 30 mg BID, 63.1% (111/176) and 47.7% (84/176), respectively; placebo, 65.3% (115/176) and 51.1% (90/176), respectively.
†Data as observed.
BID, twice daily; DMARD, disease modifying antirheumatic drug; MASES; Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
- Wells A, Edwards CJ, Kivitz A, et al. Long-term (4-year) efficacy and safety of apremilast monotherapy in DMARD-naïve subjects with active-psoriatic arthritis. Presented at: the 2017 ACR/ARHP Annual Meeting; November 3-8, 2017; San Diego, CA.